Completion of the Tender Offer by Novartis
In a significant strategic move, Novartis has announced the conclusion of its tender offer to acquire Regulus Therapeutics, a company committed to advancing innovative therapies. This acquisition is a pivotal part of Novartis’ ongoing mission to reimagine medicine and expand its capabilities within the field of biotechnology.
Details of the Tender Offer
The tender offer, executed through Redwood Merger Sub Inc., an indirectly wholly owned subsidiary of Novartis, aimed to acquire all outstanding shares of common stock of Regulus Therapeutics. Each share was offered at a cash value of $7.00, along with one contingent value right (CVR) that could yield additional funds upon the achievement of specific regulatory milestones. This offer officially expired at 11:59 p.m. New York City time on June 24, 2025.
Acquisition Impact
As of the expiry time, approximately 56 million shares were validly tendered, showcasing robust support from shareholders and representing about 74.49% of the total outstanding shares prior to the expiration. The transaction is anticipated to close shortly after, signifying a new chapter both for Novartis and Regulus Therapeutics as they endeavor to redefine therapeutic possibilities.
Expectations Post-Acquisition
With this acquisition, Novartis aims to not only enhance its innovative pipeline but also to broaden its reach within the global markets. This step reflects Novartis’ commitment to improving healthcare outcomes through advanced medicines and therapies, directly benefiting patients worldwide.
Novartis’ Vision and Commitment
Novartis is not just about medications; it's about making a significant impact on patients’ lives. By integrating Regulus’ innovative technologies and treatments into its operations, Novartis will enhance its ability to deliver cutting-edge solutions to pressing healthcare challenges. Novartis strives to empower individuals facing serious diseases, contributing to a healthier society.
About Novartis
As a leader in the field of healthcare, Novartis continually works to innovate and advance the science of medicine. With nearly 300 million people benefiting from their products globally, the company's reach is broad, and their commitment deep. Novartis emphasizes research and development, ensuring that they remain at the forefront of pharmaceutical advancements.
Contact Information for Further Inquiries
Novartis Media Relations
E-mail: media.relations@novartis.com
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com
Frequently Asked Questions
What was the tender offer price for Regulus shares?
The tender offer price was set at $7.00 per share, plus one contingent value right (CVR).
When did the tender offer expire?
The tender offer officially expired at one minute past 11:59 p.m. on June 24, 2025.
How many shares were tendered?
Approximately 56,374,397 Shares were validly tendered as of the expiration time.
What are the next steps following the tender offer?
The transaction is expected to close promptly following the acceptance of all validly tendered shares.
Who can be contacted for more information?
For media inquiries, contact the Novartis Media Relations team. For investor-related questions, reach out to the Novartis Investor Relations.
